News

European regulators said that Eli Lilly’s Alzheimer’s treatment Kisunla should be approved for select patients.
Eli Lilly & Co. won the backing of European Union regulators for its Alzheimer’s disease drug Kisunla in a specific group of patients, potentially paving the way for it to become the second drug in ...
Eli Lilly has cleared a major hurdle in its bid to win European approval for its Alzheimer's disease drug Kisunla.
Eli Lilly and Company (NYSE: LLY) announced today that the European Medicines Agency's (EMA) Committee for Medicinal Products ...
The global canine arthritis treatment market is set for substantial expansion, projected to grow from an estimated USD 2.50 ...
China's Sciwind Biosciences is in talks with a U.S. company interested in licensing its experimental weight-loss drug for ...
The initiative shifts the conversation on obesity from personal blame to scientific understanding, emphasising it as a ...
Reddit is surging with advertiser demand; not everyone is Substack material; and Trump released his AI Action Plan.
It’s understandable. When the path ahead is unclear, the instinct is to pause. To wait.
Eating disorder centers are facing an influx of people with weight-loss prescriptions. Experts say doctors are ...
We came across a bullish thesis on Eli Lilly and Company on Stock Analysis Compilation’s Substack. In this article, we will ...
Eli Lilly is walking through the Gate, inking a deal worth up to $856 million with a biotech aiming to build out a new small ...